On the stock market since 2021, it operates in the world of health and science. It has 2,100 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 24% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 17% a year on average.
The company sells $805.5M a year; the problem isn’t sales — it’s costs running above that number.
There is $466.1M in the vault; even if every debt were paid off, $104M would remain.
A loss of $130.4M against $805.5M in annual sales.
The stock trades 10% above the average analyst price target.
On our five-subject report card, SGFY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SGFY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.